ArticleJournal of virology1999
Potent inhibition of human immunodeficiency virus type 1 (HIV-1) gene expression and virus production by an HIV-2 tat activation-response RNA decoy.
Article in Journal of virology, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 46 citations in OpenAlex.
- The Confluence of HIV-1 and HIV-2: Implications for Disease Progression and Insights for Therapy.International journal of microbiology · 2025Review
- HIV-2 inhibits HIV-1 gene expression via two independent mechanisms during cellular co-infection.Journal of virology · 2023Article
- Aptamers for Viral Detection and Inhibition.ACS infectious diseases · 2022Review
- HIV-1 outcompetes HIV-2 in dually infected Senegalese individuals with low CD4⁺ cell counts.AIDS (London, England) · 2013Article
- Antiviral Stratagems Against HIV-1 Using RNA Interference (RNAi) Technology.Evolutionary bioinformatics online · 2013Article
- 5'-Triphosphate-RNA-independent activation of RIG-I via RNA aptamer with enhanced antiviral activity.Nucleic acids research · 2012Article
- Molecular recognition elements: DNA/RNA-aptamers to proteins.Biochemistry (Moscow) Supplement. Series B, Biomedical chemistry · 2010Review
- Therapeutic applications of DNA and RNA aptamers.Oligonucleotides · 2009Review
- Genetic recombination between human immunodeficiency virus type 1 (HIV-1) and HIV-2, two distinct human lentiviruses.Journal of virology · 2008Article
- Molecular strategies to inhibit HIV-1 replication.Retrovirology · 2005Review
- A nucleolar TAR decoy inhibitor of HIV-1 replication.Proceedings of the National Academy of Sciences of the United States of America · 2002Article
- Modulation of the typical multidrug resistance phenotype by targeting the MED-1 region of human MDR1 promoter.Gene therapy · 2000Article
- In vitro correlates of HIV-2-mediated HIV-1 protection.Proceedings of the National Academy of Sciences of the United States of America · 2000Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Tat activation-response region (TAR) decoys have been developed for use in gene therapy for people infected with human immunodeficiency virus type 1 (HIV-1). When a TAR RNA decoy is overexpressed, it will bind Tat, thus leaving less of this crucial protein to bind to and activate the natural transcriptional promoter of HIV-1. Previous TAR decoy constructs have used HIV-1 TAR. However, recent epidemiological and biological data began to suggest that the TAR region from the human immunodeficiency virus type 2 (HIV-2) may suppress HIV-1 transcription and hence replication. We created a vector which overexpresses TAR-2 under the control of the human U6 small nuclear RNA gene promoter and here show that the U6-TAR-2 decoy construct potently inhibits both HIV-2 and HIV-1 gene expression. Further, this decoy construct is able to markedly suppress HIV-1 replication. Thus, we have directly proven that TAR-2 can suppress HIV-1 replication and suggest that the HIV-2 TAR decoy may prove useful for combating HIV-1 infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.